JPMorgan Chase & Co. Sells 191,848 Shares of Altimmune, Inc. (NASDAQ:ALT)

JPMorgan Chase & Co. decreased its holdings in Altimmune, Inc. (NASDAQ:ALT - Free Report) by 65.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 100,912 shares of the company's stock after selling 191,848 shares during the quarter. JPMorgan Chase & Co. owned 0.14% of Altimmune worth $620,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. Larson Financial Group LLC purchased a new stake in Altimmune during the third quarter valued at $31,000. XTX Topco Ltd purchased a new stake in shares of Altimmune during the 2nd quarter valued at about $96,000. Stifel Financial Corp lifted its stake in shares of Altimmune by 77.4% in the 3rd quarter. Stifel Financial Corp now owns 17,752 shares of the company's stock worth $109,000 after purchasing an additional 7,746 shares during the period. Creative Planning boosted its holdings in shares of Altimmune by 20.5% in the third quarter. Creative Planning now owns 18,411 shares of the company's stock worth $113,000 after buying an additional 3,132 shares during the last quarter. Finally, Centiva Capital LP bought a new stake in Altimmune during the third quarter valued at approximately $120,000. Institutional investors own 78.05% of the company's stock.

Altimmune Price Performance

Shares of ALT traded down $0.02 during mid-day trading on Tuesday, reaching $6.98. 1,120,575 shares of the company's stock traded hands, compared to its average volume of 2,239,987. The stock's 50-day moving average is $7.88 and its two-hundred day moving average is $7.20. Altimmune, Inc. has a 12 month low of $5.28 and a 12 month high of $14.84. The stock has a market cap of $496.42 million, a P/E ratio of -4.50 and a beta of 0.22.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts' consensus estimates of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million for the quarter. During the same quarter in the previous year, the company posted ($0.39) earnings per share. Research analysts predict that Altimmune, Inc. will post -1.35 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently weighed in on ALT shares. Stifel Nicolaus initiated coverage on Altimmune in a research report on Wednesday, January 8th. They set a "buy" rating and a $18.00 price objective on the stock. HC Wainwright reiterated a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research report on Wednesday, January 22nd. Finally, UBS Group started coverage on shares of Altimmune in a research report on Tuesday, November 12th. They set a "buy" rating and a $26.00 price objective on the stock. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $20.83.

Altimmune Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.